Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAUMACELL: WJ-UC-MSC for Severe TBI
NCT06146062Phase 2Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2024
- Primary completion
- Aug 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Wharton's Jelly-derived Mesenchymal Stromal Cells in traumatic brain injury (TBI) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Post-traumatic neuroinflammation measured in corpus callosum by PET-MRI at 6 months. Started Jun 2024; status: recruiting.
02
Drugs
Wharton's Jelly-derived Mesenchymal Stromal Cells
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT06146062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06146062.